Metformin improves hemodynamic and rheological responses to L-arginine in NIDDM patients

Diabetes Care

Volumn 19, Issue 9, 1996, Pages 934-939

  Marfella, Raffaele ^a   Acampora, Rita ^a   Verrazzo, Giovanni ^a   Ziccardi, Patrizia ^a   De Rosa, Nicoletta ^a   Giunta, Riccardo ^a   Giugliano, Dario ^a,b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ARGININE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; NORADRENALIN;

ADRENALIN BLOOD LEVEL; ADULT; ARTICLE; BLOOD VISCOSITY; CLINICAL ARTICLE; DIASTOLIC BLOOD PRESSURE; FEMALE; GLUCOSE BLOOD LEVEL; HEART RATE; HUMAN; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INTRAVENOUS DRUG ADMINISTRATION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NORADRENALIN BLOOD LEVEL; ORAL DRUG ADMINISTRATION; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE AGGREGATION;

EID: 0029778182     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.19.9.934     Document Type: Article

References (41)

1. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE: Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 333:550-554, 1995
2. DeFronzo RA, Goodman AM, and the Multicenter Metformin Study Group: Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 333:541-549, 1995
3. Dunn CJ, Peters DH: Metformin: a review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 49:721-749, 1995
4. United Kingdom Prospective Diabetes Study Group: United Kingdom prospective diabetes study (UKPDS) 13: relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. Br Med J 310:83-88, 1995
5. Colwell JA: Vascular thrombosis in type II diabetes mellitus. Diabetes 42:8-11, 1993
6. Moncada S, Higgs A: Mechanisms of disease: the L-arginine-nitric oxide pathway. N Engl J Med 329:2002-2012, 1993
7. Nakaki T, Hishikawa K, Suzuki H, Saruta T, Kato R: L-arginine-induced hypotension (Letter). Lancet ii:696, 1990
8. Bode-Bogër SM, Böger RH, Creutzing A, Tsikas D, Gutzki F-M, Alexander K, Frölich JC: L-arginine infusion decreases peripheral arterial resistance and inhibits platelet aggregation in healthy subjects. Clin Sci 87:303-310, 1994
9. Mehta S, Stewart DJ, Hussain S, Levy RD: L-arginine produces systemic vasodilation and increases nitric oxide excretion in expired gas in humans (Abstract). Circulation 90: 138, 1994
10. Paton WDM: L-arginine induced hypotension (Letter). Lancet 336:1016, 1990
11. Smulders RA, Stehouwer CDA, Olthof CG, van Kamp GJ, Teerlink T, de Vries PMJM, Donker ABJM: Plasma endothelin levels and vascular effects of intravenous L-arginine infusion in subjects with uncomplicated insulin-dependent diabetes mellitus. Clin Sci 87:37-43, 1994
12. Parati G, Casadei R, Groppelli A, Di Rienzo M, Mancia G: Comparison of finger and intra-arterial blood pressure monitoring at rest and during laboratory testing. Hypertension 13:647-655, 1989
13. Born AV: Aggregation of blood platelet by adenosine diphosphate and its reversal. Nature 94:927-929, 1962
14. Reid HL, Barnes AJ, Lock PJ, Dormandy JA, Dormandy TL: A simple method for measuring erythrocyte deformability. J Clin Pathol 29:855-858, 1976
15. Giugliano D, De Rosa N, Di Maro G, Marfella R, Acampora R, Buoninconti R, D'Onofrio F: Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women. Diabetes Care 16:1387-1390, 1993
16. Marfella R, Verrazzo G, Acampora R, La Marca C, Giunta R, Lucarelli C, Paolisso G, Ceriello A, Gingliano D: Glutathione reverses systemic hemodynamic changes induced by hyperglycemia in healthy subjects. Am J Physiol 268:E1167-E1173, 1995
17. Stroes ESG, Koomans HA, de Briun TWA, Rabelink TJ: Vascular function in the forearm of hypercholesterolemic patients off and on lipid-lowering medication. Lancet 346:467-471, 1995
18. Baudouin SV, Bath P, Martin JF, DuBois R, Evans R: L-arginine infusion has no effects on systemic hemodynamics in normal volunteers, or systemic and pulmunary hemodynamics in patients with elevated pulmonary vascular resistance. Br J Clin Pharmacol 36:45-49, 1993
19. MacAllister RJ, Calver AL, Collier J, Edwards CBM, Herrebos B, Nussey SS, Vallance P: Vascular and hormonal responses to arginine: provision of substrate for nitric oxide or non-specific effects? Clin Sci 89:183-190, 1995
20. Kharitonov SA, Lubec G, Lubec B, Hjelm M, Barnes PJ: L-arginine increases exhaled nitric oxide in normal human subjects. Clin Sci 88:135-139, 1995
21. Cooke JP, Tsao PS: Cytoprotective effects of nitric oxide. Circulation 88:251-254, 1993
22. Giugliano D, Marfella R, Verrazzo G, Acampora R, Donzella C, Quatraro A, Coppola L, D'Onofrio F: Abnormal rheologicalal effects of glyceryl trinitrate in patients with non-insulin-dependent diabetes mellitus and reversal by antioxidants. Ann Intern Med 123:338-343, 1995
23. Koenig W, Sund M, Lowe GD, Resch KL, Turnstall-Pedse H, Keil U, Ernst E: Geographical variations in plasma viscosity and relation to coronary events rates. Lancet 344:711-714, 1994
24. Baron AD: Hemodynamic action of insulin. Am J Physiol 267:E187-E202, 1994
25. Tesfamariam B, Brown ML, Deykin D, Coehn RA: Free radicals mediate endothelium cell dysfunction caused by elevated glucose. Am J Physiol 263:H321-H326, 1992
26. Bohlen MW, Hildebrandt DA, Mizelle HL, Hall JE: Sustained hyperglycemia rapidly suppresses EDRF-mediated vasodilation of normal rat arterioles. Am J Physiol 265: H219-H225, 1993
27. Meraji M, Jayakody L, Senaratne PJ, Thomson ABR, Kappagoda K: Endothelium-dependent relaxation in aorta of BB rat. Diabetes 36:978-981, 1987
28. Durante W, Sen AK, Sunahara FA: Impairment of endothelium-dependent relaxation in aortae from spontaneously diabetic rats. Br J Pharmacol 94:463-468, 1988
29. de Tejada SIS, Goldstein I, Azadzoi K, Krane RJ, Coehn RA: Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. N Engl J Med 320:1025-1030, 1989
30. Giugliano D, Ceriello A, Paolisso G: Diabetes mellitus, hypertension and cardiovascular disease: which role for oxidative stress? Metabolism 44:363-368, 1995
31. Elliott TG, Cockcroft JR, Groop P-H, Viberti GC, Titter JM: Inhibition of nitric oxide synthesis in forearm vasculature of insulin-dependent diabetic patients: blunted vasoconstriction in patients with albuminura. Clin Sci 85:687-693, 1993
32. Zenere BM, Arcari G, Saggiani F, Rossi L, Muggeo M, Lechi A: Noninvasive detection of functional alterations of the arterial wall in IDDM patients with or without microalbuminuria. Diabetes Care 18:975-982, 1995
33. McVeigh G, Brennan H, Hayes R, Johnston D: Primary nitrate tolerance in diabetes mellitus. Diabetologia 37:115-117, 1994
34. Nagi DK, Yudkin JS: Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects: a study of two ethnic groups. Diabetes Care 16:621-629, 1994
35. Dunn CJ, Peters DH: Metformin: a review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 49:721-749, 1995
36. Landin K, Tengborn L, Smith U: Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors. J Intern Med 229:181-187, 1991
37. Sirtori CR, Franceschini G, Gianfranceschi G, Sirtori M, Montanari G, Bosisio E, Mantero E, Bondioli A: Metformin improves peripheral vascular flow in non hyperlipidemic patients with arterial disease. J Cardiovasc Pharmacol 6:914-923, 1984
38. Butterfield J: The circulation in diabetes, from HL523 to the NO era. Lancet 342: 533-536, 1993
39. Adams MR, Forsyth C, Robinson J, Jessup W, Celermajer DS: Oral L-arginme in humans: effects on platelet aggregation, hemodynamics and endothelium-dependent dilation (Abstract). Circulation 90:1138, 1994
40. Sirtori CS, Pasik C: Re-evaluation of a biguanide, metformin: mechanism of action and tolerability. Pharmacol Res 30:187-228, 1994
41. U.K. Prospective Diabetes Study Group: U.K. Prospective Diabetes Study 16: overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 44:1249-1258, 1995